Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.


TSX:OPS - Post by User

Post by Nadia6519on Nov 27, 2022 9:18am
238 Views
Post# 35131816

This morning's La Presse _ Richard Dufour

This morning's La Presse _ Richard DufourPositive sentiment in spite of tweak in rating from Raymond James (my comment).


Opsens
 fait toujours l’unanimit sur Bay Street, mais un analyste a ajust sa recommandation mardi aprs que l’entreprise de Qubec spcialise en instrumentation mdicale eut prsent sa performance de fin d’exercice. Rahul Sarugaser, de la firme Raymond James, propose toujours l’achat de l’action, mais avec un peu plus de retenue. Sa suggestion passe simplement « achat », alors qu’elle tait prcdemment un strong buy. Cet expert continue d’afficher une forte confiance dans le potentiel commercial du nouveau fil guide d’Opsens pour les procdures de remplacement de la valve aortique par cathter. Il croit cependant que le titre fluctuera court terme tant donn le contexte macroconomique qui met sous pression les multiples d’valuation dans le secteur des technologies mdicales.
<< Previous
Bullboard Posts
Next >>